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Patients with acute iliofemoral deep vein thrombosis (DVT) suffer the most severe postthrombotic sequelae. The majority of
physicians treat all patients with acute DVT with anticoagulation alone, despite evidence that postthrombotic chronic ve-
nous insufficiency, leg ulceration, and venous claudication are common in patients treated only with anticoagulation. The
body of evidence to date in patients with iliofemoral DVTsuggests that a strategy of thrombus removal offers these patients
the best long-term outcome. Unfortunately, currently published guidelines use outdated experiences to recommend against
the use of techniques designed to remove thrombus, ignoring recent clinical studies showing significant benefit in patients
who have thrombus eliminated. Contemporary venous thrombectomy, intrathrombus catheter-directed thrombolysis, and
pharmacomechanical thrombolysis are all options that can be offered to successfully remove venous thrombus with increas-
ing safety. The authors review evidence supporting the rationale for thrombus removal and discuss the most effective
approaches for treating patients with acute iliofemoral DVT.
Keywords: Deep venous thrombosis; Catheter-directed thrombolysis; Venous thrombectomy; Pharmacomechanical throm-
bolysis; Percutaneous mechanical thrombectomy.Introduction
Anticoagulation alone is the treatment used by most
physicians for patients with acute deep venous
thrombosis (DVT). Unfortunately, the extent of throm-
bosis has little or no bearing on the management
decisions made by physicians when treating acute
DVT.
The American College of Chest Physicians (ACCP)
6th Consensus Conference on Antithrombotic Ther-
apy further diminished enthusiasm by physicians to
adopt any strategy of thrombus removal as a result
of their statements regarding operative venous throm-
bectomy and thrombolytic therapy. Buller et al.1 stated
that ‘‘in patients with DVT, we recommend against
the use of venous thrombectomy (Grade 1C).’’ The
committee goes on to say that ‘‘surgical thrombec-
tomy is commonly complicated by a recurrence of
thrombus formation.’’ Unfortunately, the authors
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over 40 years ago.2,3 The follow-up of these patients
was incomplete and biased. Only 50% of the patients
originally treated underwent follow-up and only
25% had repeat phlebography. As most physicians
know, patients who have the worst clinical outcomes,
in these cases postthrombotic morbidity, represent
the majority of patients who return for follow-up
care. Patients who have minimal or no ongoing
symptoms are less likely to seek additional long-
term medical care. It is unclear how Buller et al.1
could have overlooked a randomized trial of venous
thrombectomy vs. anticoagulation with long-term
follow-up.4e6 This prospective study documented
significant benefit in patients randomized to throm-
bus extraction.
The ACCP consensus conference section stated that
‘‘there is no evidence that supports the use of throm-
bolytic agents for the initial treatment of DVT.’’1 They
recommended against the routine use of catheter-
directed thrombolysis (Grade 1C), and they went on to
state that thrombolytic therapy be confined to patients
requiring limb salvage (Grade 2C). Most physicians
recognize that delivery of a thrombolytic agent into
the thrombus is considerably more effective thanrved.
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basic mechanism of thrombolysis, which occurs by
way of activation of fibrin-bound plasminogen.7 A
randomized trial8 and a vast clinical experience have
demonstrated the improved effectiveness of catheter-
directed intrathrombus delivery of plasminogen
activators.9e11
Despite evidence demonstrating that patients with
iliofemoral venous thrombosis suffer more severe
postthrombotic morbidity than patients with infrain-
guinal deep venous thrombosis,12e14 the majority of
physicians treat all patients with acute DVT with anti-
coagulation alone. A treatment approach that includes
a strategy of thrombus removal and optimal anticoa-
gulation15 has not been adopted by most clinicians,
even in patients with the most extensive form of
venous thrombosis.
It appears that patients with iliofemoral DVT are
a clinically relevant subset of patients with acute
DVT who suffer severe postthrombotic morbidity.12e14
Following anticoagulation alone for management of
iliofemoral DVT, postthrombotic chronic venous in-
sufficiency, leg ulceration, and venous claudication
are common.12e14 It is the thesis of this report that
when one considers the body of evidence to date in
patients with extensive DVT, a strategy of thrombus
removal is the preferred management and offers
patients the best long-term outcome.Eur J Vasc Endovasc Surg Vol 33, March 2007Rationale for Thrombus Removal
The pathophysiology of chronic venous insufficiency is
ambulatory venous hypertension, defined as an ele-
vated venous pressure during exercise.16 Ambulatory
venous pressure in the lower leg and foot generally
drops to less than 50% of the standing venous pressure
in normal individuals. In patients with the postthrom-
botic syndrome, the ambulatory venous pressure drops
very little, and in individuals with persistent venous
occlusion, the ambulatory venous pressure may actu-
ally rise above standing pressure. This degree of
ambulatory venous hypertension often leads to the
debilitating symptoms of venous claudication.
The anatomic components contributing to
ambulatory venous hypertension are venous valvular
incompetence and luminal obstruction. Studies con-
sistently demonstrate that the most severe postthrom-
botic morbidity is associated with the highest venous
pressures, which occur in patients with valvular in-
competence accompanied by luminal venous obstruc-
tion.16,17 Venous obstruction is not synonymous with
occlusion. Occlusion is complete obliteration of the lu-
men, whereas obstruction (in most patients) is relative
narrowing of the lumen (Fig. 1). Unfortunately, tech-
nology has not advanced to the point that allows
physicians to assess the pathophysiologic impact of
partial luminal obstruction in an individual patient.Fig. 1. (A) Ascending phlebogram in a patient who had iliofemoral DVT 10 years earlier showed chronic venous disease
with ‘‘no evidence of obstruction,’’ as stated on the x-ray report. Three-second maximal venous outflow performed with
impedance plethysmography. A classic Linton procedure, which includes ligation of the femoral vein distal to its junction
with the profunda, was performed. A cross-section of the femoral vein (B) illustrates recanalisation of the femoral vein with
multiple channels showing significant luminal obstruction.
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struction into proper pathophysiologic perspective
in terms of its contribution to postthrombotic morbid-
ity. Therefore, there is widespread underappreciation
regarding the importance of luminal obstruction con-
tributing to postthrombotic morbidity.
Experimental observations in canine models of
acute DVT demonstrated that thrombolysis preserves
endothelial function and valve competence immedi-
ately and at four weeks after therapy compared with
placebo. There was less residual thrombus in veins
treated with a plasminogen activator, thereby preserv-
ing the vein’s structural integrity.18,19
These experimental observations translate into
improved clinical outcomes as observed in a natural
history study of acute DVT in patients treated with
anticoagulation.20e22 These investigators found that
patients with persistent proximal vein obstruction
developed distal valvular incompetence, even when
distal veins were not involved with thrombus.20 They
confirmed that the combination of venous obstruction
and valve incompetence was associated with the most
severe postthrombotic morbidity.21 Spontaneous clot
lysis naturally restored venous patency. Interestingly,
if spontaneous lysis occurred early (within 90 days),
valve function was frequently preserved.22 It is intui-
tive that successful elimination of thrombus (sponta-
neous, mechanical, or pharmacologically accelerated)
will eliminate luminal obstruction and increase the
likelihood of preservation of valve function. It follows
that, in patients whose thrombus is resolved (or elim-
inated), postthrombotic morbidity will be avoided or
significantly reduced.
Outcomes of a Strategy of Thrombus Removal
Contemporary venous thrombectomy
Advances in all methods of elimination of thrombus
from the deep venous system have occurred during
the past 10e15 years. Contemporary venous throm-
bectomy has substantially improved the early and
long-term results of patients with extensive DVT com-
pared to the initial reports.4e6,23e32 Major technical
advances between the initial and contemporary proce-
dures are listed in Table 1. The technical details of con-
temporary venous thrombectomy have been recently
reported.30,33
An important randomized trial was reported by
the Scandinavian investigators, comparing operative
venous thrombectomy and arteriovenous fistula ver-
sus anticoagulation alone in patients with iliofemoral
venous thrombosis. Peer-reviewed reports occurredat 6 months,4 5 years,5 and 10 years6 of follow-up.
Patients randomized to venous thrombectomy demon-
strated improved patency (P< 0.05), lower venous
pressures (P< 0.05), less edema (P< 0.05), and fewer
postthrombotic symptoms (P< 0.05) compared to anti-
coagulation. Interestingly, more patients undergoing
venous thrombectomy preserved normal venous valve
function in their femoropopliteal segment than patients
treated with anticoagulation alone. Hence, elimination
of iliofemoral thrombus (and proximal venous obstruc-
tion) protected the distal valves from the hemodynamic
consequences of obstructed proximal veins and resul-
tant valvular incompetence of the distal veins.20
Catheter-directed thrombolysis
The mechanism by which thrombolysis results in clot
dissolution is the activation of fibrin-bound plasmino-
gen to form the active enzyme plasmin, which dis-
solves clot.7 During thrombosis, GLU-plasminogen
(circulating) is converted to LYS-plasminogen (in
thrombus) as a result of binding to fibrin. LYS-
plasminogen has more binding sites for plasminogen
activators and is more efficiently activated to plasmin
than GLU-plasminogen. Intrathrombus delivery natu-
rally protects plasminogen activators from neutraliza-
tion by circulating plasminogen activator inhibitor
(PAI-1) and also protects the resultant active enzyme
plasmin from instantaneous neutralization by circu-
lating antiplasmins. Catheter-directed delivery of
plasminogen activators into the thrombus accelerates
thrombolysis, increasing the likelihood of a successful
outcome. Accelerated lysis reduces the overall dose
and duration of plasminogen activator infusion; there-
fore, it is reasonable to expect that complications also
will be reduced.
Numerous reports have emerged demonstrating
favorable outcomes of catheter-directed thrombolysis
for acute DVT.9e11,34e38 Three large reports document
approximately an 80% success rate9e11 (Table 2).
Table 1. Venous thrombectomy: comparison of old and contempo-
rary techniques
Technique Old Contemporary
Pretreatment phlebography/CT scan Occasionally Always
Venous thrombectomy catheter No Yes
Operative fluoroscopy/phlebography No Yes
Correct iliac vein stenosis No Yes
Arteriovenous fistula No Yes
Infrainguinal thrombectomy No Yes
Intraoperative thrombolysis No Yes
Full post op anticoagulation Occasionally Yes
Catheter-directed anticoagulation No Yes
Intermittent pneumatic compression
post op
No YesEur J Vasc Endovasc Surg Vol 33, March 2007
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treatment had been restricted only to patients with
acute iliofemoral DVT. However, as clinicians gained
confidence with the technique, patients with more
chronic thrombus were treated, resulting in lower
overall success rates. In these 3 studies, 422 patients
were treated with consistent rates of success and com-
plications. Importantly, underlying iliac vein stenoses
were treated with balloon angioplasty, stenting, or
both to achieve unobstructed venous drainage into
the vena cava, thereby reducing the risk of recurrent
thrombosis.
Major bleeding complications occurred in 5e10%
of cases, with the majority occurring at the puncture
site. Fortunately, intracranial bleeding was rare,
occurring in only 3 patients in the National Venous
Registry.10 Symptomatic pulmonary embolism (PE)
occurred in 1% of patients in the series reported by
Bjarnason et al.9 and the National Venous Registry10
and fatal PE occurred in only one out of the 422 pa-
tients. Therefore, death as a result of catheter-directed
thrombolysis was rare.
An interesting therapeutic approach was reported
by Chang et al.36 when they used intrathrombus bolus
dosing of rt-PA in 12 lower extremities of 10 patients
with acute DVT. They infused rt-PA intrathrombus
using the pulse-spray technique, limiting a single
treatment session to 50 mg. Following the pulse-spray
bolus, patients were returned to their rooms and
Table 2. Results of catheter-directed thrombolysis with urokinase
in three contemporary series: efficacy and complications
Bjarnason,
et al.9 (n¼ 77)
Mewissen,
et al.10 (n¼ 287)
Comerota,
et al.11 (n¼ 58)
Efficacy
Initial Success 79% 83% 84%
Iliac 63% 64% 78%
Femoral 40% 47% e
Primary Patency
at 1 yr
Iliac 63% 64% 78%
Femoral 40% 47% e
Iliac Stent: Patency
at 1 yr
þStent 54% 74% 89%
Stent 75% 53% 71%
Complications
Major Bleed 5% 11% 9%
Intracranial
Bleeding
0% <1% 0%
Pulmonary
Embolism
1% 1% 0%
Fatal Pulmonary
Embolism
0% 0.2% 0%
Death Secondary
to lysis
0% 0.4% 0% (?2%)*
* Death due to multiorgan system failure 30-days post lysis,
thought not related to lytic therapy.Eur J Vasc Endovasc Surg Vol 33, March 2007brought back the following day for repeat phlebo-
graphic evaluation and repeat infusion if necessary.
Treatment was repeated up to four times. Eleven of
the 12 extremities had significant or complete lysis,
and one had 50e75% lysis. Although the average total
dose of rt-PA was 106 mg, bleeding complications
were minor and no patient dropped their haematocrit
more than 2%. This intriguing technique deserves fur-
ther study to evaluate its applicability to the general
population of DVT patients.
The National Venous Registry10 reported 287 pa-
tients treated in both academic and community med-
ical centres. Sixty-six percent had acute DVT, 16% had
chronic, and 19% had an acute episode superimposed
upon a chronic condition. Seventy-one percent of the
patients presented with iliofemoral DVT and 25%
with femoropopliteal DVT. Catheter-directed throm-
bolysis with intrathrombus infusion of urokinase
(UK) was the preferred approach. In the subgroup
of patients with acute, first-time iliofemoral DVT,
65% of the patients enjoyed complete clot resolution.
During follow-up, thrombus-free survival was ob-
served in 65% at 6 months and in 60% at 12 months.
There was a significant correlation (P< .001) of
thrombus-free survival with the results of initial ther-
apy. Seventy-eight percent of patients with complete
clot resolution initially had patent veins at 1 year,
compared to only 37% of those in whom <50% of the
clot was dissolved. Interestingly, in the subgroup of
patients with acute, first-time iliofemoral DVT who
had initially successful thrombolysis, 96% of the veins
remained patent at 1 year. In addition to sustained
patency, early success directly correlated with valve
function at 6 months. Sixty-two percent of patients
with <50% thrombolysis had venous valvular incom-
petence, whereas 72% of patients who had complete
lysis had normal valve function (P< .02).
Patients with iliofemoral DVT treated in the
National Venous Registry were compared to a contem-
porary cohort of patients with iliofemoral DVT treated
with anticoagulation alone in the same institutions.39
Anticoagulated patients were candidates for lytic
therapy but were treated with anticoagulation alone
due to physician preference. A validated quality-
of-life (QOL) questionnaire was used to query patients
at 16 and 22 months post treatment. Of the 98 patients
evaluated, 68 were treated with catheter-directed
thrombolysis and 30 treated with anticoagulation
alone. Those treated with catheter-directed thrombol-
ysis reported significantly better QOL than those
treated with anticoagulation alone.39 Quality-of-life
results were directly related to the initial success of
thrombolysis. Patients who had a successful lytic out-
come reported a significantly better health utilities
355Treatment of Acute Iliofemoral Deep Venous Thrombosisindex, better physical functioning, less stigma of
chronic venous disease, less health distress, and fewer
overall postthrombotic symptoms. Patients in whom
catheter-directed thrombolysis failed had similar out-
comes to patients treated with anticoagulation alone.
These efficacy data combined with the observed re-
duction in complications with intrathrombus infusion
of plasminogen activators offer a solid argument for
the management of patients with iliofemoral DVT
with catheter-directed thrombolysis.
Subsequently, a randomized trial was performed
by Elshawary et al.40 comparing catheter-directed
thrombolysis to anticoagulation alone. These authors
demonstrated that catheter-directed thrombolysis
offered significantly better outcomes at 6 months.
Assuming patients are properly managed with antico-
agulation, this six-month observation should reflect
their long-term outcome.
Pharmacomechanical Thrombolysis
No fewer than 10 percutaneous mechanical thrombec-
tomy techniques have been developed. There appears
to be a higher incidence of embolic complications with
mechanical thrombectomy. Pulse-spray pharmacome-
chanical thrombolysis of clotted hemodialysis grafts
has demonstrated an 18% incidence of PE in patients
treated with a plasminogen activator pulse-spray so-
lution compared to a 64% incidence of PE in patients
treated with a heparinised saline pulse-spray solution
(P¼ .04).41 Since the haemodialysis graft is in direct
communication with the venous circulation, it ap-
pears that results in these patients should be similar
to patients with proximal acute DVT. However, one
would expect observations to be magnified when
treating thromboses in the much larger veins.
In an experimental model comparing mechanical,
pharmacomechanical, and pharmacologic thromboly-
sis, Greenberg and associates42 reported findings con-
sistent with Kinney et al.41 Greenberg et al.42
demonstrated that pulse-spray mechanical thrombec-
tomy was associated with the largest number and
greatest size of distal emboli. Embolic particles dimin-
ished in number and size and the speed of lysis
increased when a plasminogen activator (UK) was
added to the pulse-spray solution. Catheter-directed
thrombolysis alone was associated with the slowest
rate of reperfusion but also the fewest number of dis-
tal emboli. Generally speaking, pharmacomechanical
thrombectomy alone most often is inadequate. Hemo-
lytic complications of rheolytic mechanical thrombec-
tomy are common and occasionally can result in
anemia and renal dysfunction.Several percutaneous mechanical thrombectomy
devices have recently been used either alone or in con-
junction with thrombolytic therapy for acute iliofe-
moral DVT. A number of devices deserve further
mention. The Amplatz device utilizes a rotational
blender-like impeller design rotating at 100,000 to
150,000 rpm to aspirate and re-circulate macerated
thrombus. Removal of thrombus is reported at
75e83% in lower extremity acute DVT with 6 month
patency of 77%.43,44 Although transient procedural-
related desaturation resolved shortly after catheter
deactivation, there were no occurrences of clinically
significant PE.44
Rotational design was also adopted by the Arrow-
Trerotola device, consisting of 4 helically arranged
nitinol wires driven by a handheld battery-powered
engine rotating the catheter head at 3000 rpm. Throm-
bus is macerated and re-circulated. In vitro studies
have shown 99% thrombus removal by weight with
no remaining thrombus within the synthetic silicon
grafts.45 When used clinically in addition to thrombo-
lytic therapy and angioplasty with stents, technical
and clinical success was reported in 100% of patients
with a 16-month clinical success of 92%.46 Concerns
with valve and intimal damage, although justified,
have not been reported.46
The AngioJet device has an entirely different de-
sign, using a high-velocity saline jet (350e450 km/hr)
to produce a zone of negative pressure (760 mmHg)
around the catheter tip. Theoretical advantages of
this design include less vessel trauma and the ability
to aspirate thrombus particles through the exhaust
port. In a study without adjunctive preprocedural
thrombolytic therapy, Kasirajan et al.47 reported that
half of the patients treated had 50% of their throm-
bus removed. Patency was restored in 77% of those
patients with 50% thrombus removal. Improved
results have been observed in a similar study in which
the AngioJet was used without preprocedural throm-
bolytics.48 Sixty-five percent of patients had complete
thrombus removal while partial thrombus removal
was observed in the remaining 35%.48
A new device recently released for segmental and
controlled pharmacomechanical thrombolysis is the re-
engineered Trellis catheter (Bacchus Vascular, Santa
Clara, CA). This is a hybrid catheter which isolates
the thrombosed vein segment between two occluding
balloons. The plasminogen activator is infused into
the thrombus between the occluding balloons. A dis-
persion wire is inserted into the catheter, resulting in
the catheter shaft assuming a spiral configuration
that, when activated, spins at 1500 rpm. After 15e
20 minutes, the liquefied and particulate thrombus is
aspirated. Phlebographic evaluation of the result isEur J Vasc Endovasc Surg Vol 33, March 2007
356 A. J. Comerota and D. PaoliniFig. 2. (A, B) Ascending phlebogram of a patient presenting with phlegmasia cerulea dolens of his left leg. Phlebogram
shows extensive venous thrombosis of the femoral vein inclusive of the iliac vein which extends to the junction with the
vena cava. Not shown is thrombus in the posterior tibial and popliteal veins. The patient was treated with segmental phar-
macomechanical thrombolysis. (C) The Trellis catheter (Bacchus Vascular, Santa Clara, CA) is in place with balloons inflated.
Segmental pharmacomechanical thrombolysis successfully lysed clot (D) and restored patency to the iliofemoral venous
system. The posterior tibial and popliteal thrombosis was treated with ultrasound-accelerated thrombolysis using the
EKOS LysUS system (EKOS Corp, Bothell, WA). (E) The EKOS catheter was inserted into the posterior tibial vein at the an-
kle and advanced into the popliteal vein. (FeH) Completion ascending phlebography demonstrates complete clot lysis from
the posterior tibial vein to the vena cava. The patient’s leg normalized and he became asymptomatic.performed before treating additional segments of
thrombosed vein. The advantages of such a device
are its ability to incorporate mechanical and pharma-
cologic therapies, even in patients with a contraindica-
tion to thrombolytic therapy, since the infusate is
aspirated, and the rapidity with which treatment
can be achieved. The rationales behind the design
of this catheter are 1) rapidly resolving thrombusEur J Vasc Endovasc Surg Vol 33, March 2007during a short course of treatment, 2) limiting or
avoiding systemic thrombolysis by reducing expo-
sure to plasminogen activators as a result of aspirat-
ing liquefied thrombus and infused plasminogen
activator, and 3) preventing PE by proximal balloon
occlusion. A clinical trial designed to evaluate the
success and complication rate of this technique is cur-
rently underway.
357Treatment of Acute Iliofemoral Deep Venous ThrombosisFig. 2. (continued)The emission of ultrasound waves from an infusion
catheter delivering the plasminogen activator is an in-
teresting new adjunct to catheter-directed thromboly-
sis. Reports have emerged indicating that an infusion
catheter with ultrasound transducers built into the in-
fusion end of the catheter accelerates thrombolysis.49e52
Ultrasound enhancement of the fibrinolytic activity of
tissue plasminogen activator has been observed in
vitro.53e55 This effect is the result of clot fibrin frag-
mentation, increasing exposed fibrin surface and
thereby allowing greater tPA binding to fibrin due
to its larger available surface area.56,57 In vivo
models58 and clinical trials59 are now underway to as-
sess the potential value of ultrasound enhancement of
thrombolysis for the management of acute DVT.
A patient presenting with phlegmasia cerulea do-
lens two days after laparotomy (Fig. 2) illustrates the
advantage of using segmental pharmacomechanical
thrombolysis and ultrasound-accelerated catheter-
directed thrombolysis in order to shorten treatment
duration and limit exposure of the thrombolytic agent,
yet maximizing the chance of a successful result.
Thrombolysis is effective in restoring venous
patency and has become safer with the direct intra-
thrombus infusion and adjunctive mechanical tech-
niques. As technology continues to improve and as
direct clot-dissolving pharmacologic agents are devel-
oped,60,61 lytic infusion times should considerably
shorten and complication rates will be significantly
reduced.Recommendations for Management of Patients
with Iliofemoral DVT
The general treatment strategy for patients with acute
iliofemoral DVT is summarized in the algorithm illus-
trated in Fig. 3. Few patients need to be treated as an
emergency; however, all patients are immediately an-
ticoagulated, placed in snug, long-leg, multilayered
compression bandages extending from the base of
the toes to the upper thigh, and treated with leg eleva-
tion.62 Patients are encouraged to ambulate following
anticoagulation. When not ambulating, patients are in
bed with their legs elevated.
A rapid computed tomography (CT) scan with con-
trast is performed of the chest, abdomen, and pelvis to
evaluate for PE and other pathology, which may be as-
sociated with their aggressive degree of thrombosis
(Fig. 4). Patients who are physically active are consid-
ered for a strategy of thrombus removal. Generally,
for patients who are minimally active or have an ex-
pected lifespan of less than 2 years, anticoagulation
with compression is recommended. Patients who
have a free-floating thrombus in their vena cava usu-
ally have a vena caval filter inserted prior to catheter-
directed thrombolysis.
Patients considered for a strategy of thrombus re-
moval who have a contraindication to thrombolysis are
treated either with a contemporary venous thrombec-
tomy30 or segmental pharmacomechanical thrombolysis
using the Trellis catheter. Patients who have noEur J Vasc Endovasc Surg Vol 33, March 2007
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directed thrombolysis, usually with the addition of
pharmacomechanical techniques. Once the thrombus is
removed, patients are evaluated for an underlying ve-
nous lesion, which should be corrected to provide unob-
structed venous drainage into the vena cava, thereby
reducing the risk of recurrent thrombosis. Subsequently,
early and long-term therapeutic anticoagulation is im-
portant to avoid recurrent thrombosis. Intermittent pneu-
matic compression units are applied while patients are in
bed during their hospitalization.
Therapeutic long-term anticoagulation is important
to avoid recurrent thrombosis. Since these patients
have demonstrated an aggressive propensity for
thrombosis compared to the majority of DVT patients,
we tend to treat these patients with a longer duration
of anticoagulation, at least one year with most patients
treated much longer. These patients generally have
a low risk of bleeding complications but face serious
morbidity if rethrombosis occurs. When we consider
terminating anticoagulation, we obtain a venous du-
plex examination to evaluate for residual venous
thrombus,63 and we check for evidence of thrombus
activity by attaining D-dimer levels.64 If the venous
Fig. 3. Algorithm illustrating the general treatment strategy
for patients with iliofemoral DVT.Eur J Vasc Endovasc Surg Vol 33, March 2007duplex shows persistent venous thrombus and/or the
D-dimer level is elevated, anticoagulation is continued.
If an underlying aetiology for the patient’s exten-
sive venous thrombosis cannot be identified, a throm-
bophilia evaluation is performed. The majority of
these patients do not have an identifiable cause (e.g.,
metastatic or extensive cancer) for their aggressive
thrombosis; therefore, the majority undergo a throm-
bophilia evaluation.
Discussion
Postthrombotic morbidity following iliofemoral DVT
is certain.12e14 The more extensive the thrombosis
Fig. 4. CT of the chest, abdomen, and pelvis is part of the
routine evaluation of patients with iliofemoral and vena
caval thrombosis. The initial CT scan of the chest (A) dem-
onstrates an asymptomatic pulmonary embolism (arrow).
An additional cut (B) demonstrates mediastinal lymphade-
nopathy (top arrow) which is compressing the trachea pos-
teriorly (bottom arrow). Further images of the abdomen
demonstrated additional retroperitoneal lymphadenopathy
which subsequently proved to be lymphoma.
359Treatment of Acute Iliofemoral Deep Venous Thrombosisand the more active the patient, the more severe the
postthrombotic sequelae. Patients who are active and
those with an anticipated survival of 2 or more years
should be offered a strategy of thrombus removal.
Long-term benefits of a strategy of restoring ve-
nous patency have been documented in a randomized
trial of venous thrombectomy.4e6 Likewise, random-
ized trials of systemic thrombolytic therapy show
that when it is successful, patients have fewer post-
thrombotic sequelae and improved venous function
compared to patients treated with anticoagulation
alone or when lytic therapy is unsuccessful.65
Experimental observations18,19 and clinical studies
have documented improved venous function22,65
and improved QOL39 following successful elimina-
tion of the acute venous thrombus.
Currently, the key clinical question is not whether
patients will benefit, but whether methods to achieve
thrombus removal will be successful, and can be
applied safely.
Improvements in operative technique as well as
catheter-based technology now document higher rates
of success and complication rates which are accept-
able. As clinicians become more experienced with
these techniques, technology continues to improve,
and new pharmacologic agents are developed that
lyse thrombus more rapidly with fewer bleeding com-
plications, the application of these principles should
expand.
A national randomized trial is being planned,
which should definitively answer the question as to
whether a strategy of thrombus removal is more effec-
tive than anticoagulation alone in reducing post-
thrombotic sequelae. Until that trial is completed,
the available information strongly supports offering
a strategy of thrombus removal for patients with
acute, symptomatic iliofemoral DVT.
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